Amphastar Pharmaceuticals, Inc.AMPH

時価総額

$12.3億

PER

注射剤・吸入剤など製剤の大手。注射用、吸入・鼻内製品とインスリンAPIを展開。MerckのAPI事業を買収、BAQSIMIやPrimatene MISTを取得、2014年6月上場、20以上の製品候補保有、2024年に約190万株の自社株買い。米国・欧州・中国で展開。

概要財務

サマリーテーブルに戻る

	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income	-	-	-	-	-7	47	1	63	91	138	160
Loss on disposal of assets	-	-	-	-	-	-1	-0	-0	-0	-0	-0
Impairment of long-lived assets	-	-	-	-	-	-	-	-	-	3	-
Loss (gain) on interest rate swaps and foreign currency transactions, net	-	-	-	-	-	-	-	-	2	-5	3
Depreciation	13	11	12	13	15	17	20	22	24	25	28
Amortization of intangible assets	2	2	3	3	2	1	1	1	1	13	25
Operating lease right-of-use asset amortization	-	-	-	-	-	-	-	3	4	4	4
Amortization of Debt Issuance Costs	-	-	-	-	-	-	-	-	-	11	6
Equity in losses of unconsolidated affiliate	-	-	-	-	-	-	-	-0	-1	-2	-1
Share-based compensation expense	8	12	15	17	17	17	20	19	18	20	24
Changes in reserve for uncertain tax positions	-0	-0	0	0	-0	3	1	2	1	-1	1
Changes in deferred taxes, net	9	-8	4	-4	1	-5	0	-2	16	13	18
Accounts receivable, net	-1	11	-6	8	16	-7	20	15	10	26	22
Inventories	-7	-10	10	-19	6	41	-15	-1	12	2	49
Prepaid expenses and other assets	0	1	-1	5	-1	4	2	-4	2	3	11
Income tax refunds, deposits, and payable, net	-	-	-	12	-4	-1	1	-8	5	3	-7
Operating lease liabilities	-	-	-	-	-	-3	-4	-3	-3	-4	-4
Accounts payable and accrued liabilities	6	-3	-1	7	29	-12	21	3	-1	13	64
Net cash provided by operating activities	-	-	-	39	38	42	57	98	89	184	213
BAQSIMI acquisition	-	-	-	-	-	-	-	-	-	506	129
Purchases and construction of property, plant, and equipment	19	14	21	35	47	42	34	27	24	38	41
Proceeds from Sale of Property, Plant, and Equipment	-	0	-	-	0	-	-	-	0	-	-
Purchase of investments	-	-	4	6	0	9	14	17	36	145	77
Maturity of investments	-	-	3	4	0	-	12	19	28	39	126
Deposits and other assets	-	1	5	1	-0	0	1	3	1	-1	4
Net cash used in investing activities	-	-	-	-39	-42	-51	-36	-29	-33	-649	-125
Proceeds from equity plans, net of withholding tax payments	-	14	21	14	9	3	23	16	16	11	-
Proceeds from equity plans, net of withholding tax payments	-	-	-	-	-	-	-	-	-	-	5
Purchase of treasury stock	0	10	10	31	25	22	24	29	40	58	85
Debt issuance costs	-	-	-	-	-	-	-	2	0	25	1
Proceeds from Lines of Credit	25	-	-	-	0	-	1	-	-	-	18
Repayments under lines of credit	40	-	-	-	-	0	-	1	-	-	-
Proceeds from Issuance of long-term debt	27	7	10	19	8	4	6	70	-	845	-
Principal payments on long-term debt	8	9	15	10	6	6	8	37	2	319	8
Net cash provided by (used in) financing activities	-	-	-	-8	25	-4	-2	-37	-26	454	-81
Effect of exchange rate changes on cash	-	-	-	-	-	-0	0	-0	-0	-0	-0
Net increase (decrease) in cash, cash equivalents, and restricted cash	-	-	-	-	-	-13	19	32	30	-12	7
Deferred Payment For Acquisition	-	-	-	-	-	-	-	-	-	122	-
Capital Expenditures Incurred but Not yet Paid	-	-	-	-	-	11	11	9	5	4	6
Noncash Operating Lease Right Of Use Asset	-	-	-	-	-	8	5	11	2	11	19
Lease Obligation Incurred	0	0	1	-	0	0	0	0	1	-	-
Interest paid, net of capitalized interest	-	-	-	2	2	2	2	2	3	18	27
Income taxes paid	0	0	3	5	0	6	3	8	44	49	40